Storys zum Thema Medicale

01.03.2012 – 10:03
Hitachi Medical Systems Europe Holding AG
ECR 2012: Hitachi Medical Systems Europe Holding AG to present its new, combined Hitachi Aloka ultrasound portfolio and a new era in MR imaging
Zug, Switzerland (ots) - - - First ECR presentation of the combined Hitachi and Aloka ultrasound portfolio with its many highlights - New upgrades for ProSound F75 - New ergonomic lightweight ultrasound system F37 - Image fusion with Hitachi Real-time Virtual Sonography - A new era in MR imaging: the Echelon Oval ...
mehr
17.01.2012 – 13:55
TRON - Translational Oncology at University Medical Center Mainz
First preclinical proof-of-concept of mutation-based individualized cancer vaccine / Deep sequencing of immunogenic mutations may pave way for customized immunotherapy
Mainz (ots) - The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy. An interdisciplinary team of genome scientists and immunologists led ...
mehr
17.01.2012 – 11:45
Pevion Biotech AG
Pevion's therapeutic Candida vaccine generates functional B cell memory in all vaccinees
Ittigen, Switzerland (ots) - Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong ...
mehr
13.12.2011 – 11:00
Pieris AG
Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin® Program at ASH Annual Meeting
San Diego, CA, USA (ots) - Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today. ...
mehr
15.11.2011 – 11:37
Pieris AG
Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
San Francisco, California (ots) - --Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting-- Pieris AG presented the results of the Company?s first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein ...
mehr
02.11.2011 – 01:30
Qiagen N.V.
Home-based self-collected vaginal specimens detect more cervical lesions and cancers than cytology
Hilden, Germany, and Gaithersburg, Md. (ots) - Vaginal self-collection for Hybrid Capture®-based HPV testing increases screening coverage and is more sensitive than Pap smear shows a Mexican study published today online in the Lancet Promising findings published today online in the Lancet[i] from a community- based, randomized equivalence trial undertaken by public ...
mehr

14.10.2011 – 11:00
Actavis Inc.
Actavis donates EUR 2M worth of medicines to Libya
Zejtun, Malta (ots) - "We know Libya is faced with shortages of essential supplies. That's why Actavis donates EUR 2M worth of medicines to Libya now. The goods will leave Malta on Sunday and arrive in Tripoli during next week", said Actavis CEO Claudio Albrecht. "Actavis is one of the world's largest generic pharmaceutical players and takes its social responsibility very seriously." Mr. Albrecht emphasized the role of ...
mehr
04.10.2011 – 09:00
EUROSPINE, the Spine Society of Europe
EuroSpine: Press Conference Invitation / Spine Specialists meet at the international EuroSpine 2011 congress in Milan
Milan, Italy (ots) - The European congress for spine therapy, -surgery and orthopaedics will take place in Milan, Italy from 19-21 October and will attract numerous medical experts and industry specialists from around the globe. Thousands of participants will exchange their profound knowledge about latest research ...
mehr
27.09.2011 – 12:00
Helsinn Healthcare SA
Helsinn and Riemser Extend Relationship in Germany / License Agreement for Germany on New Therapy in Development for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV)
Lugano, Switzerland and Greifswald, Germany (ots) - Helsinn Healthcare SA, Switzerland and Riemser Arzneimittel AG, German licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce today the signing of a licensing agreement granting Riemser the commercialization rights for a ...
mehr
27.09.2011 – 02:30
ForaCare Suisse AG
ForaCare Suisse AG launches Bluetooth enabled Single-Device Smart Diabetes, BP Monitors
St. Gallen, Switzerland (ots) - ForaCare Suisse AG located in St. Gallen, Switzerland announced today the launch of a Bluetooth enabled innovative, smart single-unit devices for combined blood glucose and blood pressure (BP) monitoring. One device, the Comfort Pro GD 40, is approved for use by medical professionals and the other, Duo Ultima D40b, is being made ...
mehr
26.09.2011 – 14:30
Helsinn Healthcare SA
Helsinn Group is reinforcing its cancer supportive care pipeline
Lugano, Switerland (ots) - The Company has entered the Phase III clinical program for both its investigational medications anamorelin, in non-small cell lung cancer-associated anorexia/cachexia, and netupitant + palonosetron oral fixed-dose combination in chemotherapy-induced nausea and vomiting (CINV) Helsinn, the Swiss pharmaceutical Group, global leader in the segment of the prevention of chemotherapy-induced nausea ...
mehr
23.09.2011 – 12:00
Helsinn Healthcare SA
Helsinn Group and Eisai Inc. announce start of phase III clinical program of oral fixed-dose combination of Netupitant/Palonosetron (300mg/0.50mg) for prevention of CINV
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and ...
mehr

07.07.2011 – 12:00
Helsinn Healthcare SA
Palonosetron Better Prevents Nausea and Vomiting Linked to High Emetogenic Chemotherapy Lung Cancer Patients
Amsterdam, The Netherlands (ots) - New data presented at the 14th World Conference on Lung Cancer in Amsterdam, The Netherlands, show the efficacy of the 2nd generation 5-HT3 receptor antagonist alone and in combination with aprepitant New data on the 2nd generation 5-HT3 receptor antagonist palonosetron, in the ...
mehr
25.06.2011 – 16:30
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
ERA-EDTA congress 2011: Late Breaking Clinical Trials II / Lowering LDL cholesterol does not significantly slow down CKD progression
Prague (ots) - The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatin leads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract ...
mehr
24.06.2011 – 16:30
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
ERA-EDTA congress 2011: Late Breaking Clinical Trials I / RAVE study: In ANCA-associated vasculitis rituximab is just as effective and safe as standard therapy
Prague, Czech Republic (ots) - The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course ...
mehr
23.05.2011 – 11:00
Pieris AG
Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin(R) PRS-080 Hepcidin Antagonist Drug Program / Data to be presented at BioIron Society Meeting in Vancouver
Freising (ots) - Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood. PRS-080 showcases Anticalins' ability to encapsulate small targets like hepcidin ...
mehr
10.05.2011 – 14:00
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
XLVIII ERA-EDTA Congress in Prague from 23 June to 26 June 2011
Prag (ots) - The congress of the ERA-EDTA (European Renal Association and European Dialysis and Transplant Association) is the biggest congress in Europe on nephrology and renal replacement therapy. You are cordially invited to attend this Congress. The Opening Press Conference will be held on Thursday 23rd June, 11 am (Corinthia Hotel). Topic: Can the high level of cardiovascular risk among the European population be ...
mehr
11.04.2011 – 11:00
Pieris AG
Pieris to Present at BioCentury Future Leaders in the Biotech Industry Conference
Freising (ots) - Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium Broadway Hotel & Conference Center in New York, New York. Mr. Yoder and Dr. Laurent Audoly, Chief Scientific Officer, ...
mehr

04.04.2011 – 09:00
WMDO SA - World Medical Device Organization
WMDO Announces 100th Online Training Course for Medical Device Professionals
Ecublens, Switzerland / Minneapolis, MN (ots) - WMDO (World Medical Device Organization), the leading global provider of innovative online training for medical device professionals, announced today that it has achieved its 100th online course. Excellent reviews from industry analysts, trade associations and users in recent months have enabled WMDO to leverage growing ...
mehr
22.02.2011 – 10:00
Pieris AG
Pieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine Tri-Conference
Freising, Germany (ots) - Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin( program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, Chief Scientific Officer of Pieris, will speak on Friday, February ...
mehr
27.01.2011 – 13:00
European Society for Medical Oncology (ESMO)
International community called upon to stop the runaway train of cancer in Africa
Lugano (ots) - To coincide with World Cancer Day 2011, on 4 February, the Africa Oxford Cancer Foundation (AfrOx) and the European Society for Medical Oncology (ESMO) are working together to raise international awareness of the growing problem of cancer in Africa. AfrOx and ESMO are launching the 'Cancer in Africa: the Runaway Train' video, seeking to ...
mehr
19.01.2011 – 15:31
DAKOMED - Dachverband Komplementärmedizin
Switzerland pays for complementary medicine as part of the compulsory health insurance
Bern (ots) - Anthroposophic medicine, classic homoeopathy, neural-therapy, phytotherapy and traditional Chinese medicine will be paid for via the compulsory health insurance in Switzerland from 2012. This decision was taken by the Health Minister Didier Burkhalter on 13 January 2011. They will be included for a limited period of six years. During this period ...
mehr
11.01.2011 – 13:56
St. Gallen Oncology Conferences (SONK)
Invitation: 12th St. Gallen International Breast Cancer Conference, March 16-19, 2011
St. Gallen (ots) - This bi-annual conference will highlight meaningful advances concerning treatment of Early Breast Cancer (EBC). The conference will build up on earlier diagnostic and therapeutic recommendations and thereafter provide written guidelines for the international community. Breast cancer specialists from all over the world are awaiting these new ...
mehr
11.01.2011 – 11:20
WMDO SA - World Medical Device Organization
MDMA Announces Business Alliance with WMDO to Provide Online MedTech Industry Training MDMA Members to Receive Access to WMDO's Online Medical Device Curriculum
Washington D.C./Minneapolis, USA (ots) - MDMA (Medical Device Manufacturers Association), the leading national trade association for innovative and entrepreneurial medical technology companies and WMDO (World Medical Device Organization), the leading global provider of innovative online training for medical ...
mehr

10.01.2011 – 11:00
Pieris AG
Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration
San Francisco, USA and Freising, Germany (ots) - Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts ...
mehr
04.01.2011 – 10:00
WMDO SA - World Medical Device Organization
Medicoindustrien Announces Strategic Partnership with WMDO to Provide Online MedTech Industry Training
Niva, Denmark/Ecublens (ots) - Medicoindustrien to Compliment its Live Training Program with WMDO's Online Courses Designed Specifically for Medical Device Professionals Medicoindustrien and WMDO (World Medical Device Organization), the leading global provider of innovative online training for medical ...
mehr
23.11.2010 – 15:19
Debiopharm International SA
Abionic wins the 'Prix Debiopharm Valais pour les Sciences de la Vie' for its innovative biomedical device for diagnostic testing
Lausanne (ots) - Debiopharm Group (Debiopharm), an independent specialist in global bio-pharmaceutical development in the field of oncology and regarding certain serious diseases, has announced the winner of the Prix Debiopharm Valais pourles Sciences de la Vie (Debiopharm Valais Life Sciences Prize). ...
mehr
11.11.2010 – 10:30
Pevion Biotech AG
Pevion´s breakthrough candida vaccine demonstrates safety and immunogenicity in Phase I clinical study
Ittigen, Berne (ots) - Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women ...
mehr
11.10.2010 – 10:00
Helsinn Healthcare SA
Palonosetron more effective than granisetron in controlling nausea according to the protect study
Lugano (ots) - New data presented at the ESMO Milan 2010 Congress show a better control of nausea and vomiting with palonosetron versus granisetron in patients undergoing cisplatin or anthracycline plus cyclophosphamide based regimens. Palonosetron superior efficacy is statistically significant in nausea control, following Highly Emetogenic Chemotherapy, in the ...
mehr
04.10.2010 – 10:00
European Society for Medical Oncology (ESMO)
35th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programm CURTAIN RAISER
Lugano (ots) - Press releases will be issued during the Congress, on a daily basis. Please contact the ESMO Press Office at media@esmo.org if you would like to receive the full text of the press releases/abstracts in advance, available as of Wednesday, 6 October 2010 R. Bastian, DE Surgical ...
mehr

Vorherige39404142434445464748Nächste